# Medivir

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/medivir).

## Overview

Medivir AB is a Swedish pharmaceutical company focused on the development of innovative treatments for serious diseases. The company specializes in the research and development of small molecule drugs, with a particular emphasis on oncology and rare diseases. Medivir's portfolio includes both proprietary projects and outlicensed assets, allowing them to leverage partnerships for broader market reach. With a strong financial position and strategic collaborations, Medivir aims to advance its clinical projects and create long-term value for shareholders and patients alike.

## Products & services

• Remetinostat for skin cancer
• MIV-711 for Osteogenesis Imperfecta
• Birinapant for solid tumors
• Xerclear for labial herpes
• Veterinary drug VBX-1000 for canine periodontitis

- **Oncology** (40%) — Includes drugs for cancer treatment such as remetinostat and birinapant.
- **Rare Diseases** (30%) — Focuses on treatments for rare conditions like Osteogenesis Imperfecta.
- **Dermatology** (15%) — Includes products like Xerclear for skin conditions.
- **Veterinary Medicine** (15%) — Involves drugs for animal health, such as VBX-1000.

- Remetinostat for skin cancer
- MIV-711 for Osteogenesis Imperfecta
- Birinapant for solid tumors
- Xerclear for labial herpes
- Veterinary drug VBX-1000 for canine periodontitis

## Customers

Medivir's customer base primarily consists of pharmaceutical companies and healthcare providers seeking innovative treatments for cancer and rare diseases. The company also targets veterinary markets through partnerships for animal health products. Medivir's licensing agreements enable them to reach global markets, leveraging partners' distribution networks. Additionally, the company's focus on orphan drug designations attracts interest from stakeholders looking for exclusive market opportunities.

- **Pharmaceutical Companies** (primary) — License Medivir's oncology and rare disease treatments for distribution.
- **Healthcare Providers** (secondary) — Utilize Medivir's drugs for treating patients with rare diseases.
- **Veterinary Clinics** (emerging) — Adopt VBX-1000 for treating canine periodontitis.

- Pharmaceutical companies seeking oncology treatments
- Healthcare providers specializing in rare diseases
- Veterinary clinics and animal health companies
- Global partners for licensing and distribution
- Investors interested in orphan drug market exclusivity

## Geography

Medivir operates primarily out of Sweden, with a focus on expanding its market presence through global partnerships. The company's licensing agreements with international partners allow it to reach markets in North America and Europe. Medivir's strategic collaborations provide access to regulatory support and market exclusivity, particularly in the U.S. The company's operations are influenced by currency exposure due to contracts in multiple currencies.

- Headquartered in Sweden with global partnerships
- Licensing agreements in North America and Europe
- Currency exposure due to multi-currency contracts
- Strategic focus on U.S. market exclusivity

## Strategy

Medivir's strategic priorities include advancing its clinical pipeline, particularly in oncology and rare diseases. The company aims to leverage orphan drug designations to secure market exclusivity and regulatory support. Medivir is focused on strengthening its financial position through strategic partnerships and licensing agreements. The company also seeks to maximize the value of its projects by demonstrating clinical proof-of-concept and expanding its market reach.

- **Advance clinical pipeline** (medium-term) — To bring innovative treatments to market
- **Leverage orphan drug designations** (long-term) — To secure market exclusivity and regulatory support
- **Strengthen financial position** (short-term) — To support ongoing and future clinical developments

- Advance clinical pipeline in oncology and rare diseases
- Leverage orphan drug designations for market exclusivity
- Strengthen financial position through partnerships
- Demonstrate clinical proof-of-concept for key projects

## Risks

Medivir faces significant risks inherent in pharmaceutical development, including high costs and regulatory challenges. The company's reliance on partnerships and licensing agreements exposes it to potential market fluctuations and partner performance risks. Currency exposure due to multi-currency contracts adds financial risk. Additionally, the competitive landscape in oncology and rare diseases poses challenges to market entry and product differentiation.

- **Regulatory challenges** [critical] — Complex approval processes for new drugs
- **Currency exposure** [high] — Multi-currency contracts affecting financial stability
- **Partnership performance** [high] — Dependence on partners for market access

- High costs and regulatory challenges in drug development
- Reliance on partnerships for market access
- Currency exposure due to multi-currency contracts
- Competitive landscape in oncology and rare diseases

## Accounting

Medivir's financial statements are prepared in accordance with IFRS, with significant attention to revenue recognition from licensing agreements. The timing of revenue recognition can impact quarterly financial results, particularly with milestone payments. Currency fluctuations also affect financial reporting due to multi-currency contracts. The company must carefully manage intangible asset valuations, especially with outlicensed projects and R&D investments.

- **Revenue recognition** — high
- **Currency fluctuations** — medium

- Revenue recognition from licensing agreements
- Impact of milestone payments on quarterly results
- Currency fluctuations affecting financial reporting
- Intangible asset valuations for outlicensed projects

---

*Last updated: 2026-08-11T04:04:54.152552+00:00*